BRAF and melanoma: Untreated melanoma is not particularly immunogenic, but treatment with BRAF inhibitors causes a transient increase in antitumor immunogenicity, with recruitment of T-cells and natural killer (NK) cells and a reduction in regulatory T-cells (Tregs) [156].